New combo shows promise for tough bile duct cancer

NCT ID NCT03785873

Completed Disease control Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Feb 15, 2026 · Last updated May 14, 2026 · Updated 8 times

Summary

This study tested a mix of immunotherapy (nivolumab) and chemotherapy drugs in 34 people with advanced bile duct cancer that had gotten worse after initial treatment. The goal was to see if the combination could shrink tumors or slow the cancer's growth. The approach aims to control the disease, not cure it, and researchers monitored side effects closely.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Cancer and Hematology Centers of Western Michigan

Grand Rapids, Michigan, 49503, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States
University of Utah

Salt Lake City, Utah, 84132, United States
University of Wisconsin

Madison, Wisconsin, 53705, United States
Virginia Mason

Seattle, Washington, 98101, United States

Conditions

Explore the condition pages connected to this study.

BILIARY TRACT CANCER